logo
Plus   Neg
Share
Email

Arrowhead Pharmaceuticals Inc. (ARWR) Climbed To A New High For The Year

Arrowhead Pharmaceuticals Inc. (ARWR) announced Monday morning that it has completed enrollment of a Phase 1 clinical study of ARO-AAT. It is a potential treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

Arrowhead Pharmaceuticals rose steadily during the first 2 hours of trade Monday, before settling into a range. Shares finished with a gain of 2.66 at $13.73 on above average volume. The stock rose to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT